Adamas Pharmaceuticals Inc. (NASDAQ:ADMS)’s share price fell 3% during trading on Thursday . The company traded as low as $13.24 and last traded at $13.31, with a volume of 279,481 shares. The stock had previously closed at $13.72.

A number of brokerages have recently issued reports on ADMS. Mizuho cut their target price on shares of Adamas Pharmaceuticals from $17.00 to $16.00 and set a “neutral” rating on the stock in a research note on Thursday, May 12th. Zacks Investment Research upgraded shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, May 16th. Cowen and Company restated a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Thursday, May 12th. JMP Securities restated a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Wednesday, June 15th. Finally, Noble Financial restated a “buy” rating and issued a $25.00 target price on shares of Adamas Pharmaceuticals in a research note on Tuesday, June 28th. Two analysts have rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $32.00.

The firm’s market capitalization is $291.88 million. The firm’s 50 day moving average price is $14.57 and its 200 day moving average price is $15.30.

An institutional investor recently raised its position in Adamas Pharmaceuticals stock. Dimensional Fund Advisors LP boosted its position in shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) by 585.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 69,411 shares of the specialty pharmaceutical company’s stock after buying an additional 59,285 shares during the period. Dimensional Fund Advisors LP owned 0.38% of Adamas Pharmaceuticals worth $1,966,000 as of its most recent filing with the SEC.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.